Covid-19-associated acute kidney injury: consensus report of the 25TH ACUTE DISEASE quality initiative (ADQI) workgroup: translation of recommendations
- Authors: Gasanov M.Z1, Batyushin M.M1, Litvinov A.S2, Terentyev V.P1
-
Affiliations:
- Rostov State Medical University of the Ministry of Healthcare of Russia
- Limited liability Company «Baltic Medical Company»
- Issue: Vol 13, No 1 (2021)
- Pages: 27-49
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273739
- DOI: https://doi.org/10.18565/nephrology.2021.1.27-49
- ID: 273739
Cite item
Abstract
Full Text
About the authors
M. Z Gasanov
Rostov State Medical University of the Ministry of Healthcare of Russia
Email: mitkhat@mail.ru
MD, Cand. Med. Sci., Associate professor of Internal Medicine Department #1
M. M Batyushin
Rostov State Medical University of the Ministry of Healthcare of Russia
Email: batjushin-m@rambler.ru
MD, Doctor Med. Sci., Professor, professor of Internal Medicine Department #2
A. S Litvinov
Limited liability Company «Baltic Medical Company»
Email: dirge@yandex.ru
MD, Cand. Med. Sci., Chief
V. P Terentyev
Rostov State Medical University of the Ministry of Healthcare of Russia
Email: vpterentev@mail.ru
MD, Doctor Med. Sci., Professor, Chief of Internal Medicine Department #1
References
- Zhu N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382:727-733 (2020).
- Wang D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061-1069 (2020).
- Wang L. et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am. J. Nephrol. 51, 343-348 (2020).
- Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507-513, (2020).
- Cheng Y. et al. Kidney disease is associated with inhospital death of patients with COVID-19. Kidney Int. 97, 829-838, (2020).
- Guan W.J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708-1720 (2020).
- Wu J. et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin. Infect. Dis. 71, 706-712 (2020).
- Pei G. et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J. Am. Soc. Nephrol. 31, 1157-1165 (2020).
- Chen T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).
- Zhou F et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 (2020).
- Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS- CoV-2 pneumonia in Wuhan, China: a single- centered, retrospective, observational study. Lancet. Respir. Med. 8, 475-481 (2020).
- Cao J. et al. Clinical features and short- term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin. Infect. Dis. https://doi. org/10.1093/cid/ciaa243 (2020).
- Arentz M. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323, 1612-1614 (2020).
- Richardson S. et al. Presenting characteristics, comorbidities, and outcomes among 5700patients hospitalized with COVID-19 in the New York city area. JAMA 323, 2052-2059 (2020).
- Argenziano M.G. et al. Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series. BMJ https://doi. org/10.1101/2020.04.20.20072116 (2020).
- Hirsch J.S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 98, 209-218 (2020).
- Mohamed M.M. et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney https://doi.org/10.34067/ KID.0002652020 (2020).
- Intensive Care National Audit and Research Centre. ICNARC report on COVID-19 in critical care Case Mix Programme Database, www.icnarc.org (2020).
- Gupta S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. https://doi. org/10.1001/jamainternmed.2020.3596 (2020).
- Murugan R. et al. Acute kidney injury in non- severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 77, 527-535 (2010).
- Kellum,J.A., Bellomo, R.&Ronco C. Acute dialysis quality initiative (ADQI): methodology. Int. J. Artif. Organs 31, 90-93 (2008).
- Atkins D. et al. Grading quality of evidence and strength of recommendations. BMJ 328, 1490 (2004).
- Su H. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 98, 219-227(2020).
- Farkash E.A., Wilson A M. & Jentzen, J. M. Ultrastructural evidence for direct renal infection with SARS- CoV-2. J. Am. Soc. Nephrol. 31, 1683-1687 (2020).
- Peleg Y. et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int. Rep. 5, 940-945 (2020).
- Larsen C.P., Bourne T.D., Wilson J.D., Saqqa O. Sharshir M.A. Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19). Kidney Int. Rep. 5, 935-939 (2020).
- Kissling S. et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 98, 228-231 (2020).
- Genovese G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
- Rossi G.M. et al. Kidney biopsy findings in a critically ill COVID-19 patient with dialysis- dependent acute kidney injury: a case against “SARS- CoV-2 nephropathy”. Kidney Int. Rep. 5, 1100-1105 (2020).
- Schaller T. et al. Postmortem examination of patients with COVID-19. JAMA 323, 2518-2520 (2020).
- Santoriello D. et al. Postmortem kidney pathology findings in patients with COVID-19. J. Am. Soc. Nephrol. 31, 2158-2167(2020).
- Puelles V.G. et al. Multiorgan and renal tropism of SARS- CoV-2. N. Engl. J. Med. 383, 590-592 (2020).
- Braun F. et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 396, 597-598 (2020).
- Ackermann M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120-128 (2020).
- Liu J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS- CoV-2 infected patients. EBioMedicine 55, 102763 (2020).
- Delanghe J.R., Speeckaert M.M. & De Buyzere M.L. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin. Chim. Acta 505, 192-193 (2020).
- Othman H. et al. Interaction of the spike protein RBD from SARS- CoV-2 with ACE2: similarity with SARSCoV, hot- spot analysis and effect of the receptor polymorphism. Biochem. Biophys. Res. Commun. 527, 702-708(2020).
- Chang J.H. et al. Donor’s APOL1 risk genotype and “Second Hits” associated with de novo collapsing glomerulopathy in deceased donor kidney transplant recipients: a report of 5 cases. Am. J. Kidney Dis. 73, 134-139 (2019).
- Velez J.C.Q., Caza T.&Larse, C.P. COVAN is the new HIVAN: the reemergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 16, 565-567(2020).
- Goldstein S.L. et al. A prospective multi- center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 97, 580-588 (2020).
- Noris M., Benigni A.& Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 98, 314-322 (2020).
- Tisoncik J.R et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16-32 (2012).
- Chien J.Y., Hsueh P.R., Cheng W.C., Yu C.J.&Yang P.C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 11, 715-722 (2006).
- Chu K.H. et al. Acute renal impairment in coronavirus- associated severe acute respiratory syndrome. Kidney Int. 67, 698-705 (2005).
- Min C.K. et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci. Rep. 6, 25359 (2016).
- Teachey D.T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T- cell therapyfor acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
- Spittler A. et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin. Infect. Dis. 31, 1338-1342 (2000).
- Welch H.K., Kellum J.A.&Kane-Gill S.L. Drug-associated acute kidney injury identified in the United States food and drug administration adverse event reporting system database. Pharmacotherapy 38, 785-793 (2018).
- Ostermann M. et al. Drug management in acute kidney disease report of the acute disease quality initiative XVI meeting. Br. J. Clin. Pharmacol. 84, 396-403 (2018).
- Cuadrado-Payan E. et al. SARS-CoV-2 and influenza virus co- infection. Lancet 395, e84 (2020).
- Koyner J.L.&Murray P.T. Mechanical ventilation and lung- kidney interactions. Clin. J. Am. Soc. Nephrol. 3, 562-570 (2008).
- Dudoignon E. et al. Activation of the renin- angiotensinaldosterone system is associated with acute kidney injury in COVID-19. Anaesth. Crit. Care Pain Med. 39, 453-455 (2020).
- Li T. et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur. J. Clin. Nutr. 74, 871-875 (2020).
- Joannidis M. et al. Lung- kidney interactions in critically ill patients: consensus report of the acute disease quality initiative (ADQI) 21 workgroup. Intensive Care Med. 46, 654-672 (2020).
- Armutcu F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm. Res. 68, 825-839 (2019).
- Jin M., Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg. Infect. Dis. 26, 1618-1620 (2020).
- Sargiacomo C., Sotgia F.&Lisanti M.P. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?Aging 12, 6511-6517(2020).
- Spagnolo P. et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir. Med. 8, 750-752 (2020).
- Kashani K. et al. Quality improvement goals for acute kidney injury. Clin. J. Am. Soc. Nephrol. 14, 941-953 (2019).
- Intensive Care National Audit & Research Centre. https://www.icnarc.org (2020).
- Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2 (Suppl. 1), 1-138 (2012).
- Al- Jaghbeer M., Dealmeida D., Bilderback A., Ambrosino R.&Kellum J.A. Clinical decision support for in-hospital AKI. J. Am. Soc. Nephrol. 29, 654-660 (2018).
- Hernandez-Arroyo C.F., Varghese V., MohamedM.M.B.&Velez J.C.Q. Urinary sediment microscopy in acute kidney injury associated with COVID019. Kidney360 1, 819-823 (2020).
- Husain Syed F. et al. Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019. Nephrol. Dial. Transplant. 35, 1271-1274 (2020).
- Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 (2020).
- Wu C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934-943 (2020).
- Argenziano M.G. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 369, m1996 (2020).
- Cummings M.J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet 395, 1763-1770 (2020).
- Chen Tao et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1295 (2020).
- Nasr S.H.&Kopp J.B. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int. Rep. 5, 759-761 (2020).
- Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 45, 486-552 (2017).
- Ostermann M., Liu K.&Kashani K. Fluid management in acute kidney injury. Chest 156, 594-603 (2019).
- Douglas I.S. et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest https://doi.org/10.1016/j.chest.2020.04.025 (2020).
- Brown, R. M. et al. Balanced crystalloids versus saline in sepsis. a secondary analysis of the SMART clinical trial. Am. J. Respir. Crit. Care Med. 200, 1487-1495 (2019).
- Malbrain M. et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the International Fluid Academy (IFA). Ann. Intensive Care 10, 64 (2020).
- Self W.H. et al. Balanced crystalloids versus saline in noncritically ill adults. N. Engl. J. Med. 378, 819-828 (2018).
- Verma B. et al. A multicentre randomised controlled pilot study of fluid resuscitation with saline or Plasma-Lyte 148 in critically ill patients. Crit. Care Resusc. 18, 205-212 (2016).
- Semler, M. W. et al. Balanced crystalloids versus saline in critically ill adults. N. Engl. J. Med. 378, 829-839 (2018).
- Antequera Martin A.M. et al. Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. Cochrane Database Syst. Rev. 7, Cd012247 (2019)
- Zayed Y.Z.M. et al. Balanced crystalloids versus isotonic saline in critically ill patients: systematic review and meta- analysis. J. Intensive Care 6, 51 (2018).
- Zwager, C. L. et al. Why physiology will continue to guide the choice between balanced crystalloids and normal saline: a systematic review and metaanalysis. Crit. Care 23, 366 (2019).
- Goldstein S.L. et al. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics 132, e756-e767 (2013).
- Goldstein S.L. et al. A sustained quality improvement program reduces nephrotoxic medication- associated acute kidney injury. Kidney Int. 90, 212-221 (2016).
- Beigel J.H. et al. Remdesivirfor the treatment of Covid-19 - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).
- Dambha-Miller H. et al. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol. BJGP Open 4, bjgpopen20X101115 10.3399/bjgpopen20X101115 (2020).
- Fosbol E.L. et al. Association of angiotensinconverting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324, 168-177(2020).
- Magrone T., Magrone M.&Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin- converting enzyme 2 as a potential drug target - a perspective. Endocr. Metab. Immune Disord. Drug Targets 20, 807-811 (2020).
- Sanders J.M., Monogue M.L., Jodlowski T.Z.&Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323, 1824-1836 (2020).
- Gattinoni L. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 46, 1099-1102 (2020).
- Hering R. et al. The effects of prone positioning on intraabdominal pressure and cardiovascular and renal function in patients with acute lung injury. Anesth. Analg. 92, 1226-1231 (2001).
- Group R.C. et al. Dexamethasone in hospitalized patients with Covid-19 -preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
- Arki, N., Krishnan K., Chang M.G.&Bittner E.A. Nutrition in critically ill patients with COVID-19: challenges and special considerations. Clin. Nutr. 39, 2327-2328 (2020).
- Singer P. et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 38, 48-79(2019).
- Martindale R. et al. Nutrition therapy in critically ill patients with coronavirus disease (COVID-19). JPEN J. Parenter. Enteral Nutr. https://doi.org/10.1002/ jpen.1930 (2020).
- Barazzoni R. et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin. Nutr. 39, 1631-1638 (2020).
- Ostermann M., Macedo E.&Oudemans-van Straaten, H. How to feed a patient with acute kidney injury. Intensive Care Med. 45, 1006-1008 (2019).
- Barbar S.D. et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N. Engl. J. Med. 379, 1431-1442 (2018).
- Gaudry S. et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomized clinical trials. Lancet 395, 1506-1515 (2020).
- Gaudry S. et al. Initiation strategies for renal replacement therapy in the intensive care unit. N. Engl. J. Med. 375, 122-133 (2016).
- Zarbock A. et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 315, 2190-2199 (2016).
- Ostermann M. et al. Patient selection and timing of continuous renal replacement therapy. Blood Purif. 42, 224-237(2016).
- Palevsky P.M. et al. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359, 7-20 (2008).
- Bellomo R. et al. Intensity of continuous renal replacement therapy in critically ill patients. N. Engl. J. Med. 361, 1627-1638 (2009).
- Vesconi S. et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit. Care 13, R57 (2009).
- Claure-Del Granado R. et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin. J. Am. Soc. Nephrol. 6, 467-475 (2011).
- Joannidis M.&Oudemans-van Straaten H.M. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit. Care 11, 218 (2007).
- Adapa S. et al. COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. J. Clin. Med. Res. 12, 276-285 (2020).
- El Shamy O., Sharma S., Winston J.&Uribarri J. Peritoneal dialysis during the Coronavirus 2019 (COVID-19) pandemic: acute inpatient and maintenance outpatient experiences. Kidney Med. 2, 377-380 (2020).
- Li, L., Zhang L., Liu G.J.&Fu, P. Peritoneal dialysis for acute kidney injury. Cochrane Database Syst. Rev. 12, CD011457 (2017).
- Srivatana V. et al. Peritoneal dialysis for acute kidney injury treatment in the United States: brought to you by the COVID-19 pandemic. Kidney360 1, 410-415 (2020).
- Parienti J J. et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 299, 2413-2422 (2008).
- Marik P.E., Flemmer M.&Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and metaanalysis. Crit. Care Med. 40, 2479-2485 (2012).
- Oliver M.J., Edwards L.J., Treleaven D.J., Lambert K.&Margetts P.J. Randomized study of temporary hemodialysis catheters. Int. J. Artif. Organs 25, 40-44 (2002).
- Nahum J. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019(COVID-19). JAMA Netw. Open 3, e2010478(2020).
- Iba T. et al. The unique characteristics of COVID-19 coagulopathy. Crit. Care 24, 360 (2020).
- Iba T., Levy J H., Levi M., Connors J.M.&Thachil J. Coagulopathy of coronavirus disease 2019. Crit. Care Med. 48, 1358-1364 (2020).
- Helms J. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 46, 1089-1098 (2020).
- Chua H.R. et al. Ensuring sustainability of continuous kidney replacement therapy in the face of extraordinary demand: lessons from the COVID-19 pandemic. Am. J. Kidney Dis. 76, 392-400 (2020).
- Lempert K D.& Kopp J.B. Renal failure patients in disasters. Disaster Med. Public Health Prep. 13, 782-790 (2019).
- Durvasula R., Wellington T., McNamara E.&Watnick S. COVID-19 and kidney failure in the acute care setting: our experience from Seattle. Am. J. Kidney Dis. 76, 4-6 (2020).
- Nagatomo M. et al. Peritoneal dialysis for COVID-19-associated acute kidney injury. Crit. Care 24, 309 (2020).
- Alfano G. et al. Peritoneal dialysis in the time of coronavirus disease 2019. Clin. Kidney J. 13, 265-268 (2020).
- Ponce D., Balbi A.L., Durand J.B., Moretta G.&Divino-Filho J.C. Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury. Clin. Kidney J. 13, 269-273 (2020).
- Sourial M. Y. et al. Urgent peritoneal dialysis in patients with COVID-19 and acute kidney injury: a single-center experience in a time of crisis in the United States. Am. J. Kidney Dis. 76, 401-406 (2020).
- Griffin K.M., Karas M.G., Ivascu N.S.&Lief L. Hospital preparedness for COVID-19: a practical guide from a critical care perspective. Am. J. Respir. Crit. Care Med. 201, 1337-1344 (2020).
- Jaber S. et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR - ICU): a multicentre, openlabel, randomised controlled, phase 3 trial. Lancet 392, 31-40 (2018).
- Peacock W.F. et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double- blind, placebo- controlled study (ENERGIZE). Acad. Emerg. Med. 27, 475-486 (2020).
- Burgner A., Ikizler T.A.&Dwyer J.P. COVID-19 and the inpatient dialysis unit: managing resources during contingency planning pre-crisis. Clin. J. Am. Soc. Nephrol. 15, 720-722 (2020).
- Ronco C. & Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat. Rev. Nephrol. 16, 308-310 (2020).
- Ronco C., Reis T.&Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(20)30229-0 (2020).
- Ruan Q., Yang K., Wang W., Jiang L.&Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846-848 (2020).
- Zhou Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883-890 e882 (2020).
- Varga Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417-1418 (2020).
- Joly B.S., Siguret V&Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 46, 1603-1606 (2020).
- Honore P.M. et al. Cytokine removal in human septic shock: where are we and where are we going? Ann. Intensive Care 9, 56 (2019).
- Dellinger R.P. et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 320, 1455-1463 (2018).
- Koch B. et al. Lectin affinity plasmapheresis for middle east respiratory syndrome- coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 46, 126-133 (2018).
- Ankawi G. et al. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit. Care 22, 262 (2018).
- Gruda M.C. et al. Broad adsorption of sepsis- related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads. PLoS One 13, e0191676 (2018).
- Klein D.J. et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 44, 2205-2212 (2018).
- Cruz D.N. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445-2452 (2009).
- Knaup H. et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit. Care 22, 285 (2018).
- Busund R., Koukline V., Utrobin U.&Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 28, 1434-1439 (2002).
- Keith P. et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care 24, 128 (2020).
- Villa G. et al. Organ dysfunction during continuous veno-venous high cutoff hemodialysis in patients with septic acute kidney injury: a prospective observational study. PLoS One 12, e0172039 (2017).
- Broman M.E., Hansson F., Vincent J.L.& Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double- blind study. PLoS One 14, e0220444 (2019).
- Kacar C.K., Uzundere O., Kandemir D.&Yektas A. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous veno-venous hemodiafiltration as renal replacement therapy. Blood Purif. 49, 448-456 (2020).
- US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials. gov/ct2/show/NCT04361526 (2020).
- US National Library of Medicine. US National Library of Medicine https:// www.clinicaltrials.gov/ct2/show/NCT04324528. (2020).